Treatment Options for Metastatic Breast Cancer

Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.